Management of lipid disorders in patients living with HIV

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 957-974

  Myerson, Merle ^a   Malvestutto, Carlos ^b   Aberg, Judith A ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; cardiovascular risk factors; dyslipidemia; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILE ACID SEQUESTRANT; BOCEPREVIR; DACLATASVIR; ELVITEGRAVIR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEDIPASVIR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PARITAPREVIR; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG USE; DYSLIPIDEMIA; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MEDICAL HISTORY; META ANALYSIS (TOPIC); MIXED INFECTION; MUSCLE NECROSIS; MYALGIA; MYOGLOBINURIA; MYOPATHY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SCORING SYSTEM; SMOKING CESSATION; TREATMENT RESPONSE; WEIGHT REDUCTION; COMPLICATION; DYSLIPIDEMIAS; HIV INFECTIONS; RISK FACTOR;

ANTI-HIV AGENTS; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYPOLIPIDEMIC AGENTS; RISK FACTORS;

EID: 84937968921     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.473     Document Type: Review

References (128)

1. Dube MP, Stein JH, Aberg JA, et al., Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003; 37 (5): 613-627.
2. Lundgren JD, Battegay M, Behrens G, et al., European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008; 9 (2): 72-81.
3. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA,. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 58 (1): e1-e34.
4. Grinspoon SK, Grunfeld C, Kotler DP, et al., State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008; 118 (2): 198-210.
5. Currier JS, Lundgren JD, Carr A, et al., Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008; 118 (2): e29-e35.
6. Friis-Moller N, Thiebaut R, Reiss P, et al., DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovas Prev Rehabil. 2010; 17 (5): 491-501.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106 (25): 3143-3421.
8. Hegele RA, Ginsberg HN, Chapman MJ, et al., The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 8: 655-666.
9. Miller M, Stone NJ, Ballantyne C, et al., Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123 (20): 2292-2333.
10. Rosenson RS, Brewer HB Jr., Ansell B, et al., Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013; 128 (11): 1256-1267.
11. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr,. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011; 5 (2): 105-113.
12. Cromwell WC, Otvos JD, Keyes MJ, et al., LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management. J Clin Lipidol. 2007; 1 (6): 583-592.
13. Manickam P, Rathod A, Panaich S, et al., Comparative prognostic utility of conventional and novel lipid parameters for cardiovascular disease risk prediction: do novel lipid parameters offer an advantage. J Clin Lipidol. 2011; 5 (2): 82-90.
14. Malave H, Castro M, Burkle J, et al., Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl. Am J Cardiol. 2012; 110 (5): 662-665.
15. Swanson B, Sha BE, Keithley JK, et al., Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Spectroscopy in Medically-Underserved HIV-Infected Persons. J Clin Lipidol. 2009; 3 (6): 379-384.
16. Myerson M, Lee R, Varela D, et al., Lipoprotein measurements in patients infected with HIV: is cholesterol content of HDL and LDL discordant with particle number? J Clin Lipidol. 2014; 8 (3): 332-333.
17. Stein JH, Komarow L, Cotter BR, et al., Lipoprotein changes in HIV- Infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG Study A5152 s Stein: Lipoprotein changes on antiretroviral therapy. J Clin Lipidol. 2008; 2 (6): 464-471.
18. Riddler SA, Li X, Chu H, et al., Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007; 8 (5): 280-287.
19. Riddler SA, Li X, Otvos J, et al., Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2008; 48 (3): 281-288.
20. Alencastro PR, Fuchs SC, Wolff FH, Ikeda ML, Brandao AB, Barcellos NT,. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDS. 2011; 25 (11): 627-634.
21. Jarrett OD, Wanke CA, Ruthazer R, Bica I, Isaac R, Knox TA,. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDS. 2013; 27 (5): 266-271.
22. Friis-Moller N, Reiss P, Sabin CA, et al., Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med. 2007; 356 (17): 1723-1735.
23. Martin Lde, Pasquier S, Roudaut E,. et al. Metabolic syndrome: a major risk factor for atherosclerosis in HIV-infected patients (SHIVA study). Presse Med. 2008; 37 (4 Pt 1): 579-584.
24. Malvestutto CD, Aberg JA,. Management of dyslipidemia in HIV-infected patients. Clin Lipidol. 2011; 6 (4): 447-462.
25. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18 (6): 499-502.
26. Evans SR, Fichtenbaum CJ, Aberg JA,. Comparison of direct and indirect measurement of LDL-C in HIV- infected individuals: ACTG 5087. HIV Clin Trials. 2007; 8 (1): 45-52.
27. Baruch L, Agarwal S, Gupta B, et al., Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein. J Clin Lipidol. 2010; 4 (4): 259-264.
28. Langsted A, Freiberg JJ, Nordestgaard BG,. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008; 118 (20): 2047-2056.
29. Catapano AL, Chapman J, Wiklund O, Taskinen MR,. The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 2011; 217S: S1-S44.
30. Anderson TJ, Gregoire J, Hegele RA, et al., 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013; 29 (2): 151-167.
31. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014; 8 (1): 29-60.
32. Stone NJ, Robinson J, Lichtenstein AH, et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013.
33. Jacobson TA, Ito MK, Maki KC, et al., National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary. J Clin Lipidol. 2014; 8 (5): 473-488.
34. Parra S, Coll B, Aragones G, et al., Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med. 2010; 11 (4): 225-231.
35. Falcone EL, Mangili A, Skinner S, Alam A, Polak JF, Wanke CA,. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther. 2011; 16 (1): 1-8.
36. Law MG, Friis-Moller N, El- Sadr WM, et al., D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006; 7 (4): 218-230.
37. Zanni M, Fitch K, Feldpausch M, et al., 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014; 28: 2061-2070.
38. Ginsberg HN,. The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. Circ Res. 2014; 114 (5): 761-764.
39. Martin SS, Blumenthal RS,. Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med. 2014; 160 (5): 356-358.
40. Ridker PM, Cook NR,. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013; 382 (9907): 1762-1765.
41. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC,. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta- analysis of observational studies. Heart. 2009; 95 (22): 1826-1835.
42. Hsu R, Patton K, Liang J, Okabe R, Aberg J, Fineberg N. Independent Predictors of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, and Inflammatory Markers. Paper presented at: 7th International AIDS Conference on HIV Pathogenesis, Treatment, and Prevention. Kuala Lumpur, Malaysia July 3, 2013.
43. Post WS, Budoff M, Kingsley L, et al., Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014; 160 (7): 458-467.
44. Silverberg MJ, Leyden WA, Xu L, et al., Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 1999; 65 (2): 2014-2166.
45. Justice AC, Freiberg MS, Tracy R, et al., Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012; 54 (7): 984-994.
46. Bucher HC, Richter W, Glass TR, et al., Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999; 60 (2): 2012-2142.
47. Anastos K, Lu D, Shi Q, et al., Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 1999; 45 (1): 2007-2042.
48. Stein JH, Merwood MA, Bellehumeur JB, McBride PE, Wiebe DA, Sosman JM,. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arteriosclerosis. 2005; 25 (2): 399-405.
49. Anuurad E, Thomas-Geevarghese A, Devaraj S, et al., Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis. 2008; 198 (1): 192-197.
50. Toth PP, Barter PJ, Rosenson RS, et al., High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013; 7 (5): 484-525.
51. Davidson MH, Ballantyne CM, Jacobson TA, et al., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011; 5 (5): 338-367.
52. Marzilli M,. Pleiotropic effects of statins: evidence for benefits beyond LDL- cholesterol lowering. Am J Cardiovasc Drugs. 2010; 10 (Suppl 1): 3-9.
53. Aberg JA, Zackin RA, Brobst SW, et al., A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005; 21 (9): 757-767.
54. Calza L, Manfredi R, Colangeli V, et al., Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses. 2013; 29 (3): 547-556.
55. Aslangul E, Assoumou L, Bittar R, et al., Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010; 24 (1): 77-83.
56. Sponseller CA, m R, Campbell S, Thompson M,., Judith A,. After 52 Weeks, Pitavastatin is Superior to Pravastatin for LDL-C Lowering in Patients with HIV. Conference on Retroviruses and Opportunistic Infections March, 2014, 2014; Boston, MA.
57. Sponseller CA, Tanahashi M, Suganami H, Aberg JA,. Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV: Dyslipidemia: Post-Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor of Age. National Lipid Association Annual Scientific Sessions May 1-4, 2014; Orlando, FL.
58. Aberg JA, Sponseller CA,. Neutral Effects of Pitavastatin 4 g and Pravastatin 40 mg on Blood Glucose Levels over 12 Weeks. Prespecified Safety Analysis from INTREPID ENDO; June 16, 2013, 2013; San Francisco, CA.
59. Chauvin B, Drouot S, Barrail- Tran A, Taburet AM,. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clinical Pharmacokinet. 2013; 52 (10): 815-831.
60. Kellick K, Bottorf M, Toth P,. A clinician's guide to statin drug-drug interactions. J Clin Lipidol. 2014:: S30-S46.
61. FDA. FDA Drug Safety Communication: Interactions Between Certain HIV or Hepatitis C Drugs and Cholesterol-lowering Statin Drugs Can Increase Risk of Muscle Injury. In: FDA, ed2012.
62. Morgan ET,. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009; 85 (4): 434-438.
63. Morgan ET, Goralski KB, Piquette- Miller M, et al., Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008; 36 (2): 205-216.
64. Kohli A, Shaffer A, Sherman A, Kottilil S,. Treatment of hepatitis C: a systematic review. JAMA. 2014; 312 (6): 631-640.
65. Bichoupan K, Dieterich DT, Martel- Laferriere V,. HIV- hepatitis C virus co-infection in the era of direct-acting antivirals. Curr HIV/AIDS Rep. 2014; 11 (3): 241-249.
66. Gilead: Stribild Contraindications and Drug Interactions. (elvitegravir/cobicistat/emtricitabine/tenofovir) Prescribing information. 2014.
67. Foy M, Sperati CJ, Lucas GM, Estrella MM,. Drug interactions and antiretroviral drug monitoring. Curr HIV/AIDS Rep. 2014; 11 (3): 212-222.
68. Yu CY, Campbell SE, Sponseller CA, Small DS, Medlock MM, Morgan RE,. Steady-State Pharmacokinetics of Darunavir/Ritonavir and Pitavastatin when Co-administered to Healthy Adult Volunteers. Clinical drug investigation. 2014.
69. Kowa Pharmaceuticals America. Livalo (pitavastatin) package insert. 2014.
70. BristolMyersSquibb. Pravachol. (Pravastatin). package insert. 2014.
71. Janssen. Prezista. (darunavir) prescribing information. 2014.
72. Astra Zeneca, Crestor. (rosuvastatin) package insert. 2014.
73. lP CJ, Lee L,. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009; 53 (10): 4385-4392.
74. Pham PA, la Porte CJ, Lee LS, et al., Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009; 53 (10): 4385-4392.
75. Astra Zeneca Crestor (rosuvastatin) prescribing information. 2014.
76. Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA,. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 1999; 67 (4): 2014-2396.
77. Pfizer. Selzentry. (maraviroc) package insert. 2014.
78. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. February 28, 2012.
79. Bays H, Cohen DE, Chalasani N, Harrison SA,. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014; 8: S47-S57.
80. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA,. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014; 8: S58-S71.
81. Duggan ST,. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs. 2012; 72 (4): 565-584.
82. Neal R, Ferdinand K, Ycas J, Miller E,. Relationship of ethnic origina, gender, and age to blood creatine kinase levels. Am J Med. 2009; 122 (1): 73-78.
83. Chan P, Brew BJ,. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Current HIV/AIDS Rep. 2014; 11 (3): 317-324.
84. Sattar N, Ginsberg HN, Ray KK,. The use of statins in people at risk of developing diabetes mellitus: evicence and guideance for clinical practice. Atheroscler Suppl. 2014; 15 (1): 1-15.
85. Gilead. Sovaldi (sofosbuvir)-Important Safety Information prescribing information. 2014.
86. Gilead. Pegasys (peginterferon alfa-2a) package insert, 2014.
87. Abbvie. Moderiba (ribavirin,) package insert 2014.
88. Gilead. Harvoni (ledipasvir/sofosbuvir) package insert. 2014
89. Eley T,. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy May 21, 2014; Washington, DC.
90. Menon R, Badr iP, Khatri A,. ABT- 450/Ritonavir + Ombitavir + dasabuvir: Drug Interactions Mediated by Transporters. 15th Annual International Workshop on Clincial Pharmacology of HIV & Hepatitis Therap; May 19-21, 2014; Washington, DC.
91. Sweeny ME, Johnson RR,. Ezetimibe: an update on the mechanism of action, pharmacokinetics, and recent clinical trials. Expert Opin Drug Metab Toxicol. 2007; 3 (3): 441-450.
92. Cannon C,. Improved Reduction of Outcomes: Vytorin Efficacy International Trial American Heart Association November 17, 2014, 2014; Chicago, IL.
93. Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L,. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006; 20 (12): 1675-1677.
94. Bennett MT, Johns KW, Bondy GP,. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007; 6: 15.
95. Chow D, Chen H, Glesby MJ, et al., Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS. 2009; 23 (16): 2133-2141.
96. Digby JE, Ruparelia N, Choudhury RP,. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arteriosclerosis. 2012; 32 (3): 582-588.
97. Brunzell JD,. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007; 357 (10): 1009-1017.
98. Guyton JR, Bays HE,. Safety considerations with niacin therapy. Am J Cardiol. 2007; 99 (6A): 22C-31C.
99. Rajanna V, Campbell KB, Leimberger J, Mohanty BD, Guyton JR,. Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. J Clin Lipidol. 2012; 6 (2): 168-173.
100. Meyers CD, Carr MC, Park S, Brunzell JD,. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003; 139 (12): 996-1002.
101. Taylor AJ, Villines TC, Stanek EJ, et al., Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009; 361 (22): 2113-2122.
102. Canner PL, Berge KG, Wenger NK, et al., Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8 (6): 1245-1255.
103. Boden WE, Probstfield JL, Anderson T, et al., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365 (24): 2255-2267.
104. Landray MJ, Haynes R, Hopewell JC, et al., Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371 (3): 203-212.
105. Dube MP, Wu JW, Aberg JA, et al., Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006; 11 (8): 1081-1089.
106. Gerber MT, Mondy KE, Yarasheski KE, et al., Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis. 2004; 39 (3): 419-425.
107. Daiichi-Sankyo. Welchol (Colesevelam). package insert. 2014
108. Spence JD, Huff MW, Heidenheim P, et al., Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med. 1995; 123 (7): 493-499.
109. Nery MW, Martelli CM, Silveira EA, et al., Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal. 2013; 2013: 969281.
110. Miller J, Brown D, Amin J, et al., A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002; 16 (16): 2195-2200.
111. Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T,. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica. 2007; 37 (5): 474-486.
112. Pfizer. Lopid (Gemfibrozil) package insert 2015.
113. Calza L, Manfredi R, Chiodo F,. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection. 2002; 30 (1): 26-31.
114. Palacios R, Santos J, Gonzalez M, et al., Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 1999; 31 (2): 2002-2253.
115. Attridge RL, Frei CR, Ryan L, Koeller J, Linn WD,. Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm. 2013; 70 (14): 1219-1225.
116. Bays HE, Tighe AP, Sadovsky R, Davidson MH,. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008; 6 (3): 391-409.
117. Harris WS, Kris-Etherton PM, Harris KA,. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 2008; 10 (6): 503-509.
118. Isosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther. 2013; 55 (1415): 33-34.
119. Wohl DA, Tien HC, Busby M, et al., Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005; 41 (10): 1498-1504.
120. De Truchis P, Kirstetter M, Perier A, et al., Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 1999; 44 (3): 2007-2285.
121. Baril JG, Kovacs CM, Trottier S, et al., Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials. 2007; 8 (6): 400-411.
122. Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N,. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther. 2012; 34 (1): 67-76.
123. Gerber JG, Kitch DW, Fichtenbaum CJ, et al., Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 1999; 47 (4): 2008-2466.
124. Munoz MA, Liu W, Delaney JA, et al., Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr. 1999; 64 (3): 2013-2260.
125. Goldberg AC, Hopkins PN, Toth PP, et al., Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; S1-S8.
126. Watts GF, Gidding S, Wierzbicki AS, et al., Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation [published online ahead of print April 28, 2014]. Eur J Prev Cardiol.
127. Nguyen ST, Eaton SA, Bain AM, et al., Lipid-lowering efficacy and safety after switching to atazanavir- ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy. 2008; 28 (3): 323-330.
128. Bain AM, White EA, Rutherford WS, Rahman AP, Busti AJ,. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature. Pharmacotherapy. 2008; 28 (7): 932-938.